Pediatric Blood & Cancer · 2015 · 33 citations · 21 references
Veterinary MedicineImmunologyPediatricsImmunizationPediatric ImmunologyVaccinologyConjugate VaccinesPediatric ImmunizationVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyOpsonophagocytic ActivityPediatric VaccinationPediatric Vaccine EfficacyPneumococcal Conjugate VaccinationPneumococcal Conjugate VaccinesPneumococcal DiseasePolysaccharide VaccinesVaccine Safety In Infants
BACKGROUND: A large population of older children with sickle cell disease (SCD) is currently vaccinated with only 23-valent pneumococcal polysaccharide vaccine (PPSV23). In immunocompetent adults, PPSV23 vaccination reduces immune responses to subsequent vaccination with a pneumococcal vaccine. The 13-valent pneumococcal conjugate vaccine (PCV13), which addresses this limitation, may offer an advantage to this population at high risk of pneumococcal disease. PROCEDURE: Children with SCD 6-17 years of age previously vaccinated with PPSV23 at least 6 months before study enrollment received two doses of PCV13 6 months apart. Anti-pneumococcal polysaccharide immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured before, 1 month after each administration, and 1 year after the second administration. RESULTS: Following each PCV13 administration, IgG GMCs and OPA GMTs significantly increased, and antibody levels after doses 1 and 2 were generally comparable. Antibody levels declined over the year following dose 2. At 1 year after the second administration, OPA GMTs for all and IgG GMCs for most serotypes remained above pre-vaccination levels. Most adverse events were due to vaso-occlusive crises, a characteristic of the underlying condition of SCD. CONCLUSIONS: Children with SCD who were previously vaccinated with PPSV23 responded well to 1 PCV13 dose, and a second dose did not increase antibody response. PCV13 antibodies persisted above pre-vaccination levels for all serotypes 1 year after dose 2. Children with SCD may benefit from at least one dose of PCV13.
21
Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia
Marilyn Gaston, Joel Verter, Gerald M. Woods et al. · New England Journal of Medicine · 1986 · 1.2K citations
American Journal of Transplantation · 2012 · 690 citations · Full text
Veterinary Medicine, Infectious Diseases, Clinical Immunology +14
Sanford Leikin, Dianne Gallagher, T R Kinney et al. · PubMed · 1989 · 362 citations
Medicine, Hematology, Pediatrics +15
Mortality in Children and Adolescents With Sickle Cell Disease
Sanford Leikin, Dianne Gallagher, Thomas R. Kinney et al. · PEDIATRICS · 1989 · 316 citations
Medicine, Hematology, Pediatrics +15